CN104360083A - Detection kit for quantitatively detecting rheumatoid factors and antistreptolysin O and C reactive proteins - Google Patents
Detection kit for quantitatively detecting rheumatoid factors and antistreptolysin O and C reactive proteins Download PDFInfo
- Publication number
- CN104360083A CN104360083A CN201410736382.4A CN201410736382A CN104360083A CN 104360083 A CN104360083 A CN 104360083A CN 201410736382 A CN201410736382 A CN 201410736382A CN 104360083 A CN104360083 A CN 104360083A
- Authority
- CN
- China
- Prior art keywords
- antistreptolysin
- reactive protein
- detection
- test paper
- aso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The invention relates to the field of biological detection and particularly relates to a detection kit for quantitatively detecting rheumatoid factors and antistreptolysin O and C reactive proteins. The detection kit for quantitatively detecting rheumatoid factors and antistreptolysin O and C reactive proteins, provided by the invention, comprises a rheumatoid factor detection test paper card and an antistreptolysin O and C reactive protein detection test paper card which are independent to each other, wherein each of the rheumatoid factor detection test paper card and the antistreptolysin O and C reactive protein detection test paper card comprises a bottom plate, and a sample pad, a fluorescence marker combination pad, a nitrocellulose membrane and a water suction pad which are located on the surface of the bottom plate and are sequentially arrayed from a feeding end. According to the detection kit for quantitatively detecting rheumatoid factors and antistreptolysin O and C reactive proteins, provided by the invention, the rheumatoid factors and antistreptolysin O and CRP in rheumatism three terms are simultaneously detected for the first time by a fluorescent microsphere immunochromatography technology.
Description
Technical field
The present invention relates to field of biological detection, particularly relate to the detection kit and its production and use of a kind of quantitative detection rheumatoid factor, antistreptolysin O (ASO), c reactive protein.
Background technology
Rheumatoid factor (rheumatoid factor, RF) can be divided into IgM, IgA, IgG, IgD, IgE five type (note: be described as four types in clinical medicine, does not have IgD type; But in laboratory diagnosis, be described as 5 types), be the class autoantibody for epitope in IgG FC fragment in rheumatoid arthritis serum, rheumatoid factor positive patient is more with extra-articular manifestation, as subcutaneous nodule and vasculitis etc.IgM type RF positive rate is 60%-78%.
Body, because of after the infection A group of streptococcus such as pharyngitis, tonsillitis, scarlet fever, erysipelas, pyoderma, rheumatic fever, can produce streptolysin O antibody, i.e. " Anti-Streptolysin O (ASO) ".
Mankind's c reactive protein (C-reactive protein, CRP) refer to body be infected or tissue damage time blood plasma in some protein sharply risen (acute protein).CRP can activating complement and strengthen cytophagous engulfing and play opsonic action, thus removes the invasion pathogenic microorganism of body and damage, and downright bad, the histocyte of apoptosis, plays important protective effect in the innate immunity process of body.Research about CRP has had the history of more than 70 year, traditional view thinks that CRP is a kind of non-specific marker of inflammation, but the research of nearly ten years discloses CRP and participated in the angiocardiopathy such as inflammation and atherosclerotic directly, and be the most strong indication factor of angiocardiopathy and risk factor.
Summary of the invention
The shortcoming of prior art in view of the above, the object of the present invention is to provide detection kit of a kind of quantitative detection rheumatoid factor, antistreptolysin O (ASO), c reactive protein and its production and use, for solving the problems of the prior art.
For achieving the above object and other relevant objects, the invention provides one and quantitatively detect rheumatoid factor (RF), antistreptolysin O (ASO) (ASO), the detection kit of c reactive protein (CRP), comprise mutual independently rheumatoid factor Test paper card, antistreptolysin O (ASO) and c reactive protein Test paper card, described rheumatoid factor Test paper card, antistreptolysin O (ASO) and c reactive protein Test paper card comprise base plate all separately, and be positioned at the sample pad be arranged in order from application of sample end of backplate surface, fluorescent marker pad, nitrocellulose filter and adsorptive pads, the fluorescent marker pad of described rheumatoid factor Test paper card comprises people's sex change IgG, the fluorescent marker pad of described antistreptolysin O (ASO) Test paper card comprises hammer bacteriolysin O (SLO), the fluorescent marker pad of described c reactive protein Test paper card comprises c reactive protein monoclonal antibody, described each nitrocellulose filter is coated with detection line and nature controlling line, hammer bacteriolysin O on described fluorescent marker pad, people's sex change IgG, c reactive protein monoclonal antibody adopts fluorescent microsphere mark.
Preferably, hammer bacteriolysin O on described fluorescent marker pad, people's sex change IgG, c reactive protein monoclonal antibody adopt 180nm fluorescent microsphere mark, EX (nm)=650/Em (nm)=670, there is signal little by background interference, detection sensitivity is high, the advantage that result is reproducible.
Preferably, in order to make kit, there is better sensitivity and color developing effect, fluorescent marker described in the present invention combines pays somebody's debt and expect repayment later through pre-service, the pre-treatment buffer used in pre-service comprises following component: stachyose, alum, Fructose Diphosphate, sodium hexametaphosphate and glycocoll, and the total concentration of stachyose, alum, Fructose Diphosphate, sodium hexametaphosphate, glycocoll is 3.5-7.5g/L, the pH value of damping fluid is 7.2-7.6.
Preferably, the concentration of each component in damping fluid is:
The solvent of described pre-treatment buffer is water.
Described pretreated concrete steps are: fluorescent marker pad is soaked 1.5-2.5h in pretreatment fluid, take out and are put in 36-38 DEG C of oven dry.
Described pre-treatment buffer can use the various conventional pH adjusting agent in this area to carry out the adjustment of pH value.
Preferably, described base plate is PVC base plate.
Preferably, on described nitrocellulose filter, detection line is positioned at side close to application of sample end, and nature controlling line is positioned at side away from application of sample end.
Preferably, the detection line of described rheumatoid factor Test paper card is coated with people's sex change IgG.。
Preferably, the detection line of described antistreptolysin O (ASO) Test paper card is coated with streptolysin O.
Preferably, the detection line of described c reactive protein Test paper card is coated with c reactive protein monoclonal antibody.
Preferably, nature controlling line wraps by sheep anti-mouse antibody.
Preferably, also comprise and getting stuck, described getting stuck comprises back of the body card and upper cover, the described back of the body is arranged with three parallel test card draw-in grooves, described test card is embedded in described test card draw-in groove respectively, be covered with three testing windows and three wells on described, matching with the detection line of three test cards and the position of nature controlling line respectively in the position of described three testing windows, matches with the position of the sample pad of three test cards in the position of described three wells.
Preferred, described in get stuck for plastics get stuck.
Preferred, be also provided with the translot of connection three wells between described three wells.
Preferably, described detection kit is used for the content that simultaneous quantitative detects rheumatoid factor, antistreptolysin O (ASO), c reactive protein.
The detection kit of quantitative detection rheumatoid factor provided by the present invention, antistreptolysin O (ASO), c reactive protein adopts double antigens sandwich immunochromatographic method when detecting rheumatoid factor, antistreptolysin O (ASO), adopt double antibody sandwich method when detecting CRP, supporting immune quantitative analytical instrument uses.Immunoassay instrument, by acquisition testing line (T) and nature controlling line (C) band fluorescence signal, calculates T/C signal value.First various criterion product are added drop-wise on test card before using, analyzing and processing sets up calibration curve (relation of T/C signal value and standard items actual value), again the T/C value obtained when detecting sample is compared with typical curve, the content of the rheumatoid factor detected in sample, antistreptolysin O (ASO), c reactive protein can be obtained.
Second aspect present invention provides the preparation method of the detection kit of described quantitative detection rheumatoid factor, antistreptolysin O (ASO), c reactive protein, comprises the steps:
1) antistreptolysin O (ASO), rheumatoid factor, c reactive protein fluorescent marker pad is sprayed respectively with SLO, people's sex change IgG, the c reactive protein monoclonal antibody solution of fluorescent microsphere mark;
2) on the detection line and nature controlling line of antistreptolysin O (ASO) nitrocellulose filter, SLO and sheep anti-mouse antibody is sprayed respectively, the detection line and nature controlling line of rheumatoid factor nitrocellulose filter spray people's sex change IgG and sheep anti-mouse antibody respectively, the detection line and nature controlling line of c reactive protein nitrocellulose filter spray CRP monoclonal and sheep anti-mouse antibody respectively;
3) nitrocellulose filter, adsorptive pads prepared by the fluorescent marker pad three cover sample pad, steps 1 prepared, step 2 are pasted onto on respective base plate successively, and cutting obtains Test paper card; Finally Test paper is snapped fits into the obtained detection kit that gets stuck.
Preferably, in order to make kit, there is better sensitivity and color developing effect, fluorescent marker described in the present invention combines pays somebody's debt and expect repayment later through pre-service, the pre-treatment buffer used in pre-service comprises following component: stachyose, alum, Fructose Diphosphate, sodium hexametaphosphate and glycocoll, and the total concentration of stachyose, alum, Fructose Diphosphate, sodium hexametaphosphate, glycocoll is 3.5-7.5g/L, the pH value of damping fluid is 7.2-7.6.
Preferably, the concentration of each component in damping fluid is:
The solvent of described pre-treatment buffer is water.
Described pretreated concrete steps are: fluorescent marker pad is soaked 2h in pretreatment fluid, take out and are put in 37 DEG C of oven dry.
Third aspect present invention provides the purposes of detection kit at rheumatoid factor, antistreptolysin O (ASO), c reactive protein detection field of described quantitative detection rheumatoid factor, antistreptolysin O (ASO), c reactive protein.
Rheumatoid factor in rheumatism three, antistreptolysin O (ASO), CRP are detected by fluorescent micro-ball immune chromatography technology by the detection kit of quantitative detection rheumatoid factor provided by the present invention, antistreptolysin O (ASO), c reactive protein first simultaneously, the content of rheumatoid factor in sample, antistreptolysin O (ASO), CRP just can be detected by an application of sample operation, simplify operating process, have sensitivity and specificity concurrently, quick and precisely assess rheumatoid arthritis clinical symptoms.In addition, described detection kit has the advantages such as operation is fast and convenient, result is accurate, economic and practical, disturb little by the serious blood fat of serum (or blood plasma), haemolysis, as serum (or blood plasma) haemoglobin≤600mg/L, triglyceride≤100mg/dL, cholerythrin≤20mg/dL, variation < 10% is affected on accuracy.
Embodiment
Below by way of specific instantiation, embodiments of the present invention are described, those skilled in the art the content disclosed by this instructions can understand other advantages of the present invention and effect easily.The present invention can also be implemented or be applied by embodiments different in addition, and the every details in this instructions also can based on different viewpoints and application, carries out various modification or change not deviating under spirit of the present invention.
Before further describing the specific embodiment of the invention, should be understood that protection scope of the present invention is not limited to following specific specific embodiments; It is also understood that the term used in the embodiment of the present invention is to describe specific specific embodiments, instead of in order to limit the scope of the invention; In instructions of the present invention and claims, unless explicitly pointed out in addition in literary composition, singulative " ", " one " and " this " comprise plural form.
When embodiment provides numerical range, should be understood that except non-invention is otherwise noted, between two end points of each numerical range and two end points, any one numerical value all can be selected.Unless otherwise defined, all technology used in the present invention are identical with the meaning that those skilled in the art of the present technique understand usually with scientific terminology.Except the concrete grammar used in embodiment, equipment, material, according to those skilled in the art to the grasp of prior art and record of the present invention, any method of prior art that is similar with the method described in the embodiment of the present invention, equipment, material or that be equal to, equipment and material can also be used to realize the present invention.
Unless otherwise indicated, disclosed in the present invention experimental technique, detection method, preparation method all adopt the routine techniques of the molecular biology of the art routine, biological chemistry, chromatin Structure and analysis, analytical chemistry, cell chulture, recombinant DNA technology and association area.These technology are existing in existing document improves explanation, specifically can see the MOLECULAR CLONING:A LABORATORY MANUAL such as Sambrook, Second edition, Cold Spring HarborLaboratory Press, 1989and Third edition, 2001; Ausubel etc., CURRENT PROTOCOLS INMOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987and periodic updates; The seriesMETHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATINSTRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODSIN ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), AcademicPress, San Diego, 1999; With METHODS IN MOLECULAR BIOLOGY, Vol.119, ChromatinProtocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc.
The preparation of embodiment 1 test card of the present invention:
1) pre-treatment buffer is used to carry out pre-service to fluorescent marker pad, pre-treatment buffer is: stachyose 2g/L, alum 0.5g/L, Fructose Diphosphate 1.5g/L, sodium hexametaphosphate 0.3g/L, the aqueous solution of glycocoll 1.88g/L, pH=7.4, pretreated concrete steps are: fluorescent marker pad is soaked 2h in pretreatment fluid, take out and are put in 37 DEG C of oven dry; The SLO, the people's sex change IgG that mark with appropriate fluorescent microsphere, c reactive protein monoclonal antibody buffer solution spray pretreated fluorescent marker pad respectively, obtained three kinds of fluorescent marker pads, in solution, the mass ratio of fluorescent microsphere and label is 5:1, the concentration of solution is 10mg/ml, and quantity for spray is 4ul/cm;
2) on the detection line and nature controlling line of nitrocellulose filter, spray appropriate SLO and sheep anti-mouse antibody solution, appropriate people's sex change IgG and sheep anti-mouse antibody solution and appropriate CRP monoclonal and sheep anti-mouse antibody respectively, obtained three kinds of bags by after nitrocellulose filter, the concentration of spray solution is 1mg/ml, and quantity for spray is 1ul/cm;
3) nitrocellulose filter, adsorptive pads prepared by fluorescent marker pad sample pad, step 1 prepared, step 2 are pasted onto on respective PVC base plate successively, and cutting obtains rheumatoid factor Test paper card, antistreptolysin O (ASO), the CRP Test paper card of wide 3-5mm; Finally Test paper is snapped fits into the obtained detection kit that gets stuck.
Standard lines curve:
Be 0 by concentration respectively, 20, 50, 100, 150, 200, 250, 300, 400, the rheumatoid factor buffer solution of 500ng/mL drips in sample pad, each concentration establishes 5 repetitions (testing result gets 5 mean values repeated), after rete is analysed 10 minutes, use immunoassay instrument by acquisition testing line (T) and nature controlling line (C) band fluorescence signal, analyser be AD value 0-10000 to the sensing range of fluorescence signal, calculate T/C signal value, set up rheumatoid factor calibration curve, wherein Y-axis is T/C signal value, X-axis is standard items actual value.
Be 0 respectively by concentration, 20,50,100,150,200,250,300,400,500,600, the antistreptolysin O (ASO) buffer solution of 800pg/mL drips in sample pad, each concentration establishes 5 repetitions (testing result gets 5 mean values repeated), after rete is analysed 10 minutes, use immunoassay instrument by acquisition testing line (T) and nature controlling line (C) band fluorescence signal, calculate T/C signal value, set up antistreptolysin O (ASO) calibration curve, wherein Y-axis is T/C signal value, and X-axis is standard items actual value.
Be 0 respectively by concentration, 1,2,5,10,15,20,300,40,50,60,80, the CRP buffer solution of 100mg/L drips in sample pad, each concentration establishes 5 repetitions (testing result gets 5 mean values repeated), after rete is analysed 10 minutes, use immunoassay instrument by acquisition testing line (T) and nature controlling line (C) band fluorescence signal, calculate T/C signal value, set up CRP calibration curve, wherein Y-axis is T/C signal value, and X-axis is standard items actual value.
The detection of rheumatoid factor, antistreptolysin O (ASO), CRP content anti-interference:
Virus monitory sample drop is added in sample pad, 5 repetitions (testing result gets 5 mean values repeated) established by each sample, after rete is analysed 10 minutes, the T/C value obtained when detecting sample is compared with typical curve, obtain the detection data of the rheumatoid factor detected in sample, antistreptolysin O (ASO), CRP content, rheumatoid factor detection obtained again, antistreptolysin O (ASO), CRP content data and true rheumatoid factor, antistreptolysin O (ASO), CRP content data contrast, and obtaining accuracy affects deviate.
Sample 1:50ng/mL rheumatoid factor, 300pg/mL antistreptolysin O (ASO), 60mg/L CRP, 600mg/L haemoglobin, 100mg/dL triglyceride, 10mg/dL cholerythrin;
Sample 2:100ng/mL rheumatoid factor, 200pg/mL antistreptolysin O (ASO), 10mg/L CRP, 500mg/L haemoglobin, 50mg/dL triglyceride, 15mg/dL cholerythrin;
Sample 3:150ng/mL rheumatoid factor, 150pg/mL antistreptolysin O (ASO), 2mg/L CRP, 80mg/L haemoglobin, 20mg/dL triglyceride, 20mg/dL cholerythrin;
Sample 4:200ng/mL rheumatoid factor, 100pg/mL antistreptolysin O (ASO), 30mg/L CRP, 150mg/L haemoglobin, 30mg/dL triglyceride, 4mg/dL cholerythrin;
Sample 5:300ng/mL rheumatoid factor, 50pg/mL antistreptolysin O (ASO), 5mg/L CRP, 300mg/L haemoglobin, 80mg/dL triglyceride, 9mg/dL cholerythrin;
Blank control sample: 300mg/L haemoglobin, 80mg/dL triglyceride, 9mg/dL cholerythrin serum sample.
The rheumatoid factor content data of the detection that sample 1-5 obtains is respectively 52ng/mL, 99ng/mL, 155ng/mL, 208ng/mL, 299ng/mL, antistreptolysin O (ASO) content is respectively 285pg/mL, 211pg/mL, 147pg/mL, 110pg/mL, 48pg/mL, CRP content data is respectively 65mg/L, 9mg/L, 2mg/L, 33mg/L, 5.5mg/L, accuracy affect variation < 10%, blank does not find that obvious fluorescence signal changes.
Embodiment 2
The preparation of comparative example test card: only change pre-treatment buffer formula, the pre-treatment buffer of comparative example test card is 25mM glycine buffer, pH=7.4, and other steps are all identical with preparation process in embodiment 1.
The sensitivity of rheumatoid factor, antistreptolysin O (ASO), CRP and detectability contrast experiment:
Judge with fluorescent instrument, analyser be AD value 0-10000 to the sensing range of fluorescence signal, according to the performance of instrument, CUTOFF value is 50, under certain concentration, more than 90% test example AD value >=50, namely think that kit can be used in the detection under this concentration.
Adopt 5%BSA normal saline solution as dummy, dummy should not contain measured object.The known blood sample of rheumatoid factor getting 0.3-5.3ng/mL gradient concentration carries out sensitivity detection, arranges a gradient at interval of 0.2ng/mL, and each gradient arranges 20 samples, record testing result.The test card lowest detection of result display prepared by embodiment 1 is limited to 0.5ng/mL, and the lowest detectable limit of comparative example test card is higher than 5.3ng/mL.
Adopt 5%BSA normal saline solution as dummy, dummy should not contain measured object.The known blood sample of antistreptolysin O (ASO) getting 1-50pg/mL carries out sensitivity detection, arranges a gradient at interval of 1pg/mL, and each gradient arranges 20 samples, record testing result.The test card lowest detection of result display prepared by embodiment 1 is limited to 3pg/mL, and the lowest detectable limit of comparative example test card is higher than 50pg/mL.
Adopt 5%BSA normal saline solution as dummy, dummy should not contain measured object.The known blood sample of CRP getting 0.05-0.99mg/L carries out sensitivity detection, arranges a gradient at interval of 0.02mg/L, and each gradient arranges 20 samples, record testing result.The test card lowest detection of result display prepared by embodiment 1 is limited to 0.05mg/L, and the lowest detectable limit of comparative example test card is higher than 0.99mg/L.
In sum, detection kit provided by the present invention has good anti-interference and specificity, and has good sensitivity, and negative background is lower, effectively overcomes various shortcoming of the prior art and tool high industrial utilization.
Above-described embodiment is illustrative principle of the present invention and effect thereof only, but not for limiting the present invention.Any person skilled in the art scholar all without prejudice under spirit of the present invention and category, can modify above-described embodiment or changes.Therefore, such as have in art usually know the knowledgeable do not depart from complete under disclosed spirit and technological thought all equivalence modify or change, must be contained by claim of the present invention.
Claims (10)
1. one kind is quantitatively detected rheumatoid factor, antistreptolysin O (ASO), the detection kit of c reactive protein, comprise mutual independently rheumatoid factor Test paper card, antistreptolysin O (ASO) and c reactive protein Test paper card, described rheumatoid factor Test paper card, antistreptolysin O (ASO) and c reactive protein Test paper card comprise base plate all separately, and be positioned at the sample pad be arranged in order from application of sample end of backplate surface, fluorescent marker pad, nitrocellulose filter and adsorptive pads, the fluorescent marker pad of described rheumatoid factor Test paper card comprises people's sex change IgG, the fluorescent marker pad of described antistreptolysin O (ASO) Test paper card comprises hammer bacteriolysin O, the fluorescent marker pad of described c reactive protein Test paper card comprises c reactive protein monoclonal antibody, described each nitrocellulose filter is coated with detection line and nature controlling line, hammer bacteriolysin O on described fluorescent marker pad, people's sex change IgG, c reactive protein monoclonal antibody adopts fluorescent microsphere mark.
2. detection kit as claimed in claim 1, it is characterized in that, on described each nitrocellulose filter, detection line is positioned at side close to application of sample end, and nature controlling line is positioned at side away from application of sample end.
3. detection kit as claimed in claim 1, is characterized in that, the detection line of described rheumatoid factor Test paper card is coated with people's sex change IgG.
4. detection kit as claimed in claim 1, is characterized in that, the detection line of described antistreptolysin O (ASO) Test paper card is coated with streptolysin O.
5. detection kit as claimed in claim 1, is characterized in that, the detection line of described c reactive protein Test paper card is coated with c reactive protein monoclonal antibody.
6. detection kit as claimed in claim 1, is characterized in that, described each nature controlling line wraps by sheep anti-mouse antibody.
7. detection kit as claimed in claim 1, it is characterized in that, also comprise and getting stuck, described getting stuck comprises back of the body card and upper cover, the described back of the body is arranged with three parallel test card draw-in grooves, and described test card is embedded in described test card draw-in groove respectively, is covered with three testing windows and three wells on described, matching with the detection line of three test cards and the position of nature controlling line respectively in the position of described three testing windows, matches with the position of the sample pad of three test cards in the position of described three wells.
8. detection kit as claimed in claim 7, is characterized in that, be also provided with the translot of connection three wells between described three wells.
9. detection kit as claimed in claim 1, is characterized in that, described detection kit is used for the content that simultaneous quantitative detects rheumatoid factor, antistreptolysin O (ASO), c reactive protein.
10. the preparation method of the detection kit of the quantitative detection rheumatoid factor as described in claim as arbitrary in claim 1-9, antistreptolysin O (ASO), c reactive protein, comprises the steps:
1) antistreptolysin O (ASO), rheumatoid factor, c reactive protein fluorescent marker pad is sprayed respectively with SLO, people's sex change IgG, the c reactive protein monoclonal antibody solution of fluorescent microsphere mark;
2) on the detection line and nature controlling line of antistreptolysin O (ASO) nitrocellulose filter, SLO and sheep anti-mouse antibody is sprayed respectively, the detection line and nature controlling line of rheumatoid factor nitrocellulose filter spray people's sex change IgG and sheep anti-mouse antibody respectively, the detection line and nature controlling line of c reactive protein nitrocellulose filter spray CRP monoclonal and sheep anti-mouse antibody respectively;
3) nitrocellulose filter, adsorptive pads prepared by the fluorescent marker pad three cover sample pad, steps 1 prepared, step 2 are pasted onto on respective base plate successively, and cutting obtains Test paper card; Finally Test paper is snapped fits into the obtained detection kit that gets stuck.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410736382.4A CN104360083B (en) | 2014-12-05 | 2014-12-05 | A kind of detection by quantitative rheumatoid factor, antistreptolysin O (ASO), the detection kit of c reactive protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410736382.4A CN104360083B (en) | 2014-12-05 | 2014-12-05 | A kind of detection by quantitative rheumatoid factor, antistreptolysin O (ASO), the detection kit of c reactive protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104360083A true CN104360083A (en) | 2015-02-18 |
| CN104360083B CN104360083B (en) | 2016-08-17 |
Family
ID=52527365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410736382.4A Active CN104360083B (en) | 2014-12-05 | 2014-12-05 | A kind of detection by quantitative rheumatoid factor, antistreptolysin O (ASO), the detection kit of c reactive protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104360083B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106680508A (en) * | 2015-11-06 | 2017-05-17 | 北京中生金域诊断技术股份有限公司 | Method and kit for quantitative combined detection of PA (Prealbumin) and CRP (C-reactive Protein), as well as preparation method and application of kit |
| CN109085333A (en) * | 2018-08-22 | 2018-12-25 | 上海复星长征医学科学有限公司 | A kind of preparation, detection kit and the preparation method of rheumatoid factor antigen |
| CN112285364A (en) * | 2020-11-05 | 2021-01-29 | 南京申基医药科技有限公司 | Kit for combined detection of three items of rheumatism and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101025418A (en) * | 2006-02-23 | 2007-08-29 | 上海富纯中南生物技术有限公司 | Concatenate antigen membrane detecting kit and its preparing method |
| CN102161716A (en) * | 2010-12-30 | 2011-08-24 | 北京九强生物技术股份有限公司 | Method and reagent for latex sensitization |
| CN202149903U (en) * | 2011-05-19 | 2012-02-22 | 博阳生物科技（上海）有限公司 | Time-resolved fluorescence immune chromatography quantitative detection test strip for C-reactive protein |
| CN102707050A (en) * | 2012-05-24 | 2012-10-03 | 蓝十字生物药业（北京）有限公司 | Colloidal gold test strip for fast detecting rheumatoid factors |
| CN102879559A (en) * | 2011-07-12 | 2013-01-16 | 上海执诚生物科技股份有限公司 | Real-time quantitative detection reagent and method of time-resolved fluorescence immune chromatography |
| CN203732542U (en) * | 2013-10-17 | 2014-07-23 | 上海科新生物技术股份有限公司 | Test paper card and diagnostic kit for detecting rheumatoid arthritis |
| CN203838159U (en) * | 2014-02-26 | 2014-09-17 | 郑州浪峰生物技术有限公司 | Colloidal gold test paper strip for detecting anti-cyclic citrullinated peptide antibodies and rheumatoid factors |
-
2014
- 2014-12-05 CN CN201410736382.4A patent/CN104360083B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101025418A (en) * | 2006-02-23 | 2007-08-29 | 上海富纯中南生物技术有限公司 | Concatenate antigen membrane detecting kit and its preparing method |
| CN102161716A (en) * | 2010-12-30 | 2011-08-24 | 北京九强生物技术股份有限公司 | Method and reagent for latex sensitization |
| CN202149903U (en) * | 2011-05-19 | 2012-02-22 | 博阳生物科技（上海）有限公司 | Time-resolved fluorescence immune chromatography quantitative detection test strip for C-reactive protein |
| CN102879559A (en) * | 2011-07-12 | 2013-01-16 | 上海执诚生物科技股份有限公司 | Real-time quantitative detection reagent and method of time-resolved fluorescence immune chromatography |
| CN102707050A (en) * | 2012-05-24 | 2012-10-03 | 蓝十字生物药业（北京）有限公司 | Colloidal gold test strip for fast detecting rheumatoid factors |
| CN203732542U (en) * | 2013-10-17 | 2014-07-23 | 上海科新生物技术股份有限公司 | Test paper card and diagnostic kit for detecting rheumatoid arthritis |
| CN203838159U (en) * | 2014-02-26 | 2014-09-17 | 郑州浪峰生物技术有限公司 | Colloidal gold test paper strip for detecting anti-cyclic citrullinated peptide antibodies and rheumatoid factors |
Non-Patent Citations (2)
| Title |
|---|
| 冯景: "免疫透射比浊法测定抗链球菌溶血素O和类风湿因子", 《陕西医学检验》 * |
| 钱厚明: "风湿3项检测中C反应蛋白诊断价值的探讨", 《检验医学与临床》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106680508A (en) * | 2015-11-06 | 2017-05-17 | 北京中生金域诊断技术股份有限公司 | Method and kit for quantitative combined detection of PA (Prealbumin) and CRP (C-reactive Protein), as well as preparation method and application of kit |
| CN109085333A (en) * | 2018-08-22 | 2018-12-25 | 上海复星长征医学科学有限公司 | A kind of preparation, detection kit and the preparation method of rheumatoid factor antigen |
| CN112285364A (en) * | 2020-11-05 | 2021-01-29 | 南京申基医药科技有限公司 | Kit for combined detection of three items of rheumatism and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104360083B (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108279309B (en) | Detection test strip and detection method for PLA2R antibody | |
| CN104360085B (en) | A kind of AFP detection kit | |
| BR9609771A (en) | Process for quantitative measurement of amyloid protein a; recombinant protein; acute phase human serum specific antiserum. | |
| CN104459140B (en) | The detection kit of a kind of detection by quantitative Rheumatoid factors, polyclonal, antistreptolysin O, cyclic citrullinated peptid, c reactive protein | |
| CN105548547A (en) | Flow type array immunoassay kit for detecting lung cancer markers based on flow cytometry | |
| CN105988008A (en) | Measurement device, kit and measurement method | |
| CN104360083A (en) | Detection kit for quantitatively detecting rheumatoid factors and antistreptolysin O and C reactive proteins | |
| CN104459138B (en) | A kind of IGFBP-1 detection kit | |
| CN104374911A (en) | Detection kit for quantitative detection of rheumatoid factors and anti streptolysin O | |
| Peoples et al. | Microfluidic capillary system for immunoaffinity separations of C-reactive protein in human serum and cerebrospinal fluid | |
| CN104897905B (en) | A kind of c reactive protein gold-immunochromatographyreagent reagent for assay box | |
| CN103713121A (en) | Human vasculitis diagnostic kit and preparation method thereof | |
| CN104360080B (en) | A kind of golgiosome glycoprotein-73 detection kit | |
| US20140011190A1 (en) | Method for performing a rapid test | |
| US8501494B1 (en) | Method and device for detecting prior drug use, taking inflammation into account to increase test's specificity and reduce false positives | |
| CN104391122B (en) | A kind of AFP, PIVKA-II combined detection kit | |
| CN104374927B (en) | A kind of detection kit of quantitative detection LP(a) | |
| Alhabbab et al. | Enzyme immunoassay (EIAs) and enzyme-linked immunosorbent assay (ELISA) | |
| CN104360079B (en) | A kind of PIVKA-II detection kit | |
| CN104360082B (en) | A kind of AFP, GP73 combined detection kit | |
| CN104407155A (en) | AFP (Alpha Fetal Protein), GP (Golgi Protein)73 and PIVKA (Protein Induced By Vitamin K Absence)-II joint detection kit | |
| CN107656045A (en) | Procalcitonin near-infrared fluorescent detection reagent card, kit and application thereof | |
| CN107941742A (en) | β human chorionic gonadotrophin near-infrared fluorescent detection reagents card, kit and application thereof | |
| CN107884584A (en) | Rotavirus detection reagent card, kit and application thereof | |
| RU2702900C1 (en) | Method for quantitative determination of antibodies to benzo[a]pyrene in human biological fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171025 Address after: 400000 Taikang Road Dadukou District of Chongqing Bridge Industrial Park C District No. 6 Building 30 layer 1-4 Patentee after: Chongqing Zhongyuan Ji Ji Biological Technology Co., Ltd. Address before: Jiulongpo Branch Park four street 400039 Chongqing city 70-1, 70-2 block J No. six Patentee before: CHONGQING QIANDE BIOTECHNOLOGY CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000 Patentee after: Zhongyuan Huiji Biotechnology Co.,Ltd. Address before: Floor 1-4, building 30, no.6, Taikang Road, Zone C, Jianqiao Industrial Park, Dadukou District, Chongqing 400000 Patentee before: CHONGQING ZHONGYUAN HUIJI BIOTECHNOLOGY Co.,Ltd. |